Loading
RPH-051 is an experimental monoclonal antibody from R-Pharm in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.
RPH-051 is a monoclonal antibody developed by R-Pharm. Its target is HER2 (the sponsor names HER2). The sponsor states: A pertuzumab biosimilar candidate, a HER2-targeted monoclonal antibody given with trastuzumab and docetaxel, being tested for non-inferiority and comparability of safety/immunogenicity against reference product Perjeta. ClinicalTrials.gov describes the intervention as: RPH-051: concentrate for solution for infusion, 30 mg/mL 14 mL of the liquid concentrate is diluted with 250 mL of 0.9% sodium chloride solution. The nominal concentration of the prepared solution is 3.0 mg/mL for the loading dose and 1.6 m. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07386938 (A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer), in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT07386938, plans to enrol 246 participants with primary completion was scheduled for 2025-10-15 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A pertuzumab biosimilar candidate, a HER2-targeted monoclonal antibody given with trastuzumab and docetaxel, being tested for non-inferiority and comparability of safety/immunogenicity against reference product Perjeta. Connects to HER2.
1.RPH-051 binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RPH-051" OR ABSTRACT:"RPH-051") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RPH-051, not a curated reading list.
Shares R-Pharm and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.